HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by COHEN, C. J. Articles by WATRING, W. Search for Related Content PubMed PubMed Citation Articles by COHEN, C. J. Articles by WATRING, W.

Multidrug Treatment of Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

From the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mt. Sinai School of Medicine of the City University of New York, New York; Gynecologic Oncology Group, Roswell Park Memorial Institute, Buffalo, New York; Department of Obstetrics and Gynecology, Bowman-Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina; Department of Obstetrics and Gynecology, Jefferson Medical College, Philadelphia, Pennsylvania; and Division of Gynecologic Oncology, Kaiser Permanente Medical Group and University of California, Irvine, California

Abstract

Patients (358) with advanced (FIGO stages III and IV) or recurrent endometrial cancer were treated with one of two regimens: 1) melphalan and 5-fluorouracil daily for four days, repeated every four weeks with megace daily for eight weeks and 2) adriamycin, 5-fluorouracil, and cyclophosphamide, intravenous bolus every 21 days with megace daily for eight weeks. All patients were randomized except for 63 with known cardiac disease who were assigned to regimen 1 (to avoid adriamycin) and studied separately. Stratification was effected for performance status, history of previous progestational therapy, presence or absence of measurable disease, and stage of disease. The objective response rate in those with measurable disease was 36.8% in both groups; 36.8% of each group had stable disease, and only 26.4% progressed on treatment. Response was unaffected by site of recurrence, time to first recurrence, presence or absence of previous treatment by progestational or radiation therapy, or age. Grade of tumor and performance status did affect response, although 44 of 57 objective responders had undifferentiated tumors. The two combinations achieved response rapidly, required careful supervision, and were especially useful in treating patients with usually poor prognostic features.

This article has been cited by other articles:

				C. Humber, J. Tierney, R. Symonds, M Collingwood, J Kirwan, C Williams, and J. Green Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann. Onc., March 1, 2007; 18(3): 409 - 420. [Abstract] [Full Text] [PDF]

				O. Wada-Hiraike, H. Hiraike, H. Okinaga, O. Imamov, R. P. A. Barros, A. Morani, Y. Omoto, M. Warner, and J.-A. Gustafsson Role of estrogen receptor beta in uterine stroma and epithelium: Insights from estrogen receptor beta-/- mice PNAS, November 28, 2006; 103(48): 18350 - 18355. [Abstract] [Full Text] [PDF]

				J. T. Thigpen, M. F. Brady, H. D. Homesley, J. Malfetano, B. DuBeshter, R. A. Burger, and S. Liao Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., October 1, 2004; 22(19): 3902 - 3908. [Abstract] [Full Text] [PDF]

				W. Tong and J. W. Pollard Progesterone Inhibits Estrogen-Induced Cyclin D1 and cdk4 Nuclear Translocation, Cyclin E- and Cyclin A-cdk2 Kinase Activation, and Cell Proliferation in Uterine Epithelial Cells in Mice Mol. Cell. Biol., March 1, 1999; 19(3): 2251 - 2264. [Abstract] [Full Text] [PDF]